Metastatic castration-resistant prostate cancer (mCRPC) is an incurable condition associated with poor prognosis and reduced quality of life. Historically, treatment options were limited, and despite recent advancements, the five-year survival rate for metastatic prostate cancer remains low at approximately 34%. The current standard of care for newly diagnosed mCRPC patients includes androgen receptor pathway inhibitors such as abiraterone acetate, as well as docetaxel chemotherapy. However, the treatment landscape is evolving with the introduction of new therapies. Among these, poly (ADP-Ribose) polymerase (PARP) inhibitors, in combination with androgen receptor pathway inhibitors like talazoparib plus enzalutamide, have shown promising results in clinical trials.
However, talazoparib plus enzalutamide, abiraterone acetate and docetaxel have not been compared in head-to-head clinical trials. When such trial data is unavailable, indirect treatment comparisons (ITCs) may be used to estimate their relative efficacy.
To aid clinical decision-making in treatment selection, the Value & Evidence team at EVERSANA (Imtiaz A. Samjoo, Anja Haltner, Samantha Craigie, Di Wang, Sarah Walsh) – along with Dr. Elena Castro and the team at Pfizer Inc. (Alexander Niyazov and Jonathan Nazari) – conducted a matching-adjusted indirect comparison (MAIC) between these therapies. This technique involves matching the treatment cohorts on eligibility criteria and reweighting the matched patients in one study to align with the characteristics of those in another.
This study underscores the importance of indirect comparative evidence in the absence of head-to-head randomized clinical trials for guiding optimal treatment strategies for patients living with mCRPC. For decision-makers and clinicians, our findings offer valuable insights into the relative efficacy of these first-line treatment options.
For a deeper understanding, access the full article in Future Oncology.
Author
As Senior Director of the Value & Evidence team at EVERSANA, Imtiaz leads evidence synthesis projects that support global HEOR initiatives involving systematic literature reviews, indirect treatment comparisons, and health economic modeling, to support reimbursement…
Anja brings over 10 years of academic and industry experience in applied statistical analyses. Anja’s research focuses on population-adjusted indirect treatment comparisons including matching-adjusted indirect comparisons, simulated treatment comparisons, and propensity score matching and…
Samantha Craigie holds an MSc in Epidemiology and Biostatistics from the University of Western Ontario. As an Associate Director at EVERSANA in Evidence Synthesis, Samantha has led many global SLR and ITC projects for…
Sarah is a Manager on the Value & Evidence team at EVERSANA and provides statistical support and guidance on evidence synthesis projects. Sarah brings over six years of academic experience and a strong background…